Schneyer Mark C.'s Form 4 filing
Acadia Pharmaceuticals Inc (ACAD) · filed Mar 27, 2024
- Accession no.
- 0001415889-24-009270
- Filed
- Mar 27, 2024
- Trade date
- Mar 25-27, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market sales total $97.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schneyer Mark C.CIK 0001899977 | Officer (EVP, CHIEF FINANCIAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 25, 2024 | Common Stock | AGrant or awardAcquired | +10,550 | $0.00F1 | $0 | 31,617 | Direct | |
| Mar 27, 2024 | Common Stock | SSaleDisposed | −5,434 | $17.90 | −$97,268.6 | 26,183 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 25, 2024 | Common Stock | AGrant or awardAcquired | +80,564 | $0.00 | $0 | 80,564 | Direct | |
| Mar 25, 2024 | Common Stock | AGrant or awardAcquired | +24,714 | $0.00 | $0 | 24,714 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at 50% of target
Referenced by the price of 1 transaction in Table I.